https://www.selleckchem.com/pr....oducts/CI-1040-(PD18
The baseline mean BDV of the control, 5-, and 10-mg acemannan groups were not significantly different ( 0.05). After treatment, the mean BDV for each group was reduced in a time-dependent manner. Compared with the control group, the 5- and 10-mg acemannan groups had a significantly greater %ΔBDV (approximately 2- and 1.89-fold) at 3-months post-surgery, respectively ( 0.05). However, at the 6- and 12- month follow-up, the %ΔBDV was not significantly different between the groups. These data suggest acemannan enhanc